• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 12, Pages 189: Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
ih Shao Few studies have assessed the benefits of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PC; mPC) at an old age or with major cardiovascular conditions. A retrospective cohort consisted of 3835 men with newly diagnosed mPC from the Taiwan Cancer Registry of 2008–2014. Among them, 2692 patients received only ADT in the first year after the cancer diagnosis, and 1143 patients were on watchful waiting. The inverse probability of treatment-weighted Cox model was used to estimate the effects of ADT on all-cause mortality and PC-specific mortality according to age, and the...
Source: Cancers - January 11, 2020 Category: Cancer & Oncology Authors: Wu Fang Hwang Shih Shao Tags: Article Source Type: research

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
Androgen deprivation therapy (ADT) in the treatment of prostate cancer may be associated with an increased risk of thromboembolic disease. The aim of our study was to investigate the association of ADT in the ...
Source: BMC Cancer - December 30, 2019 Category: Cancer & Oncology Authors: Kuang-Ming Liao, Yaw-Bin Huang, Chung-Yu Chen and Chen-Chun Kuo Tags: Research article Source Type: research

No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men
This study included 1278 patients with prostate cancer in the study group and 1278 subjects without prostate cancer in the comparison group. Each patient was individually tracked for a 3‐year period to identify those who had subsequently received a diagnosis of CHD. The results showed that the incidence rate of CHD during the 3‐year follow‐up period was 4.69 (95% CI: 2.99–5.48) per 100 person‐years and 2.67 (95% CI: 2.15–3.27) per 100 person‐years for the study and comparison cohort, respectively. The Cox proportional hazard regression showed that the hazard ratio for CHD during the 3‐year follow‐up perio...
Source: Andrology - December 29, 2015 Category: Urology & Nephrology Authors: L. H. Wang, C. K. Liu, C. H. Chen, L. T. Kao, H. C. Lin, C. Y. Huang Tags: Original Article Source Type: research